Morris Plains, New Jersey-based Immunomedics announced it has halted its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC). An independent Data Safety Monitoring Committee (DSMC) recommended they stop the trial because of “compelling evidence of efficacy.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,